Reykjavik, Iceland,, February 17, 2025 / Prnewswire / – 3z Pharmaceuticals announced today the publication of a transformative study into neuropsychopharmacology, highlighting convincing scientific evidence that positions the mechanisms initiated by amlodipine, a blocking channel of calcium type L (LTCC), as the foundation of a new therapy for ADH. The results provide robust validation of the 3z high speed drug discovery platform and introduce new paths for the treatment of non-stimulating ADHD.
ADHD is a widespread neurodevelopmental disorder with limited treatment options. Current stimulating drugs, such as methylphenidate, offer advantages to some but are often associated with side effects, abuse potential and high non-response rate. 3Z Pharmaceuticals undertakes to fill these shortcomings with alternative pioneer and non -stimulating therapies.
In this newly published study, 3z researchers, inter-species behavioral tests have integrated Mendelian randomization analysis and human genetic data to demonstrate the therapeutic potential of amlodipine. The main conclusions include:
- Behavioral rescue in ADHD models: amlodipine has considerably reduced hyperactivity in hypertensive spontaneous rats and improved impulsiveness in the ADGRL3.1 – / – ADHD zebra, providing a cross validation of its efficiency.
- The penetration of the blood-brain barrier and the neuronal impact: surprisingly traditional penetration studies have confirmed that amlodipine crosses the blood-brain barrier, where it modulates neural activation, forcing the hypothesis of poor penetration cerebral.
- Genetic proof via Mendelian randomization: human genetic analysis has linked the risk of ADHD to variations in LTCC genes (CACNA1C, CACNB1, CACNA2D3), which are direct targets of amlodipine, strengthening its mechanistic potential in ADHD therapy.
- Clinical relevance in human populations: analysis of the polygenic risk score using British biobank has shown that individuals with high genetic load of ADHD who were prescribed the amlodipine presented a reduction in symptoms related to ADHD, regardless of its antihypertensive effects.
Doctor Karl Karlsson Neuroscientist, CEO of 3z pharmaceuticals and teacher of biomedical engineering at Reykjavik University, commented the impact of the study:
“This research represents a paradigm shift in the therapy of ADHD. Our results validate not only the mechanism affected by amlodipine as a promising candidate for the non -stable treatment of ADHD, but also underlines the power of our screening approaches and high -speed genetic modeling, carried out in close alliance with biotx.ai.
Based on these results, 3z Pharmaceuticals advances a variant of therapy towards clinical development, taking advantage of its established security profile and its precise action mechanism to introduce ADHD transformative therapy.
Media contact:
Name: Karl ægir Karlson
Title: CEO
3z Pharmaceuticals
E-mail: Karlsson@3z.is
Telephone: + 354-8256467
Link to paper: https://www.nature.com/articles/S41386-025-02062-x
This information was provided to you by Cionion http://news.cision.com
Show the original content:https://www.prnewswire.com/apac/News-releases/3zz-Pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-Blocker-as-Aagroundbriaking-Adhd-Therapy-30237945.Html
Source 3Z EHF
